文献速递造血干细胞移植与细胞治疗淋巴瘤

体外光分离置换法作为CAR T细胞治疗后移植物抗宿主病治疗的有前景策略

Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy.
PubMed 文献 · Blood Adv · 2024-01-01

该体外研究建立第三代CD19特异性CAR-T细胞及体外ECP方案,在非稀释模型和稀释模型中全面探究ECP对CAR-T细胞的影响,并用混合淋巴细胞反应检测ECP对GVHD的治疗作用。结果显示ECP可选择性诱导凋亡、富集初始和中枢记忆CAR-T细胞、降低同种反应性并将细胞因子环境从免疫刺激转向免疫耐受,同时不损害CAR-T细胞长期功能。

要点

  • ECP处理后的CAR-T细胞在MLR中诱导同种反应的能力较未处理组降低。
  • ECP可选择性诱导凋亡,富集初始和中枢记忆CAR-T细胞并降低同种反应性。
  • 两种模型中ECP均使CAR-T细胞因子环境从免疫刺激转向免疫耐受。

核心结论

  • ECP是异基因造血干细胞移植和CAR-T细胞输注后GVHD的有前景治疗策略,因其降低同种反应性而不损害CAR-T细胞功能。

研究设计与样本

  • 体外研究:生成第三代CD19特异性CAR-T细胞并建立体外ECP方案,在非稀释模型和稀释模型2种模型中探究ECP对CAR-T细胞的影响。
  • 用体外混合淋巴细胞反应(MLR)检测ECP对GVHD的治疗作用。

主要发现

  • MLR中ECP处理的CAR-T细胞诱导同种反应的能力较未ECP处理组降低。
  • ECP可选择性诱导凋亡,从而富集初始和中枢记忆CAR-T细胞并降低同种反应性。
  • 两种模型中CAR-T细胞的细胞因子环境均可从免疫刺激转向免疫耐受。
  • 稀释模型中ECP可调节CAR-T细胞的增殖能力而不损害其长期功能。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) occurs in about 10% to 33% of patients receiving "allogeneic" or "autologous" chimeric antigen receptor T (CAR-T) cells after preceding allogeneic hematopoietic stem cell transplantation (allo-HSCT) due to the substantial presence of alloreactive T cells. Extracorporeal photopheresis (ECP) shows promising clinical outcomes in the treatment of GVHD after allo-HSCT without hampering antitumor and antiviral effects. This raises an interesting question: whether ECP might constitute a new way to treat patients with GVHD after CAR T-cell therapy without compromising CAR-T cells significantly. Third-generation CD19-specific CAR-T cells were generated and an in vitro ECP protocol was established. The impact of ECP on CAR-T cells was comprehensively investigated in 2 models: the nondilution model reflects days after CAR T-cell infusion and the dilution model weeks after infusion. The therapeutic effect of ECP on GVHD was examined in an in vitro mixed lymphocyte reaction (MLR) assay. We found, ECP-treated CAR-T cells demonstrated reduced potency in inducing alloreaction compared with that of the group without ECP treatment in MLR assay. ECP could selectively induce apoptosis, thereby enriching the naive and central memory CAR-T cells with a reduced alloreactivity. The cytokine milieu of CAR-T cells could be switched from immune stimulation to immune tolerance in both models. Moreover, ECP could modulate the proliferative capacity of CAR-T cells without hampering their long-term functionality in the dilution model. In conclusion, ECP constitutes a promising treatment strategy for GVHD after allo-HSCT and CAR T-cell transfusion, as ECP reduces the alloreactivity without hampering CAR T-cell functionality.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Han H, Wang L, Ding Y, et al. Extracorporeal photopheresis as a promising strategy for the treatment of graft-versus-host disease after CAR T-cell therapy. Blood Adv. 2024. PMID: 38359409. doi:10.1182/bloodadvances.2023012463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。